GlassScriptPhysician profile
Aashish G Samat
NPI 1912155300
$1,722.31
in general payments reported to CMS, 2019-2025
21 companies · $299 in 2025
The $299 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $60.93 · 2021: $125 · 2022: $350 · 2023: $445 · 2024: $339 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,082.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $375.32 | 2019-2025 | Ozempic |
| Dexcom, INC. | $349.88 | 2019-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $162.99 | 2021-2025 | Evenity, Prolia, Prolia |
| Cequr Corporation | $122.25 | 2023-2025 | Cequr Simplicity |
| Lilly USA, LLC | $119.64 | 2019-2022 | |
| Corcept Therapeutics | $115.03 | 2023 | Korlym |
| Radius Health, INC. | $106.40 | 2021 | |
| Abbott Laboratories | $104.42 | 2022-2023 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $32.33 | 2023 | |
| Beta Bionics, INC. | $24.89 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic Minimed, INC. | $24.18 | 2019 | |
| Companion Medical, INC. | $24.16 | 2020 | |
| Ibsa Pharma INC. | $22.90 | 2023 | Tirosint, Licart |
| Almatica Pharma LLC | $22.33 | 2025 | Teriparatide |
| Sanofi-Aventis U.S. LLC | $21.89 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $20.26 | 2022 | |
| Antares Pharma, INC. | $16.26 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.13 | 2025 | |
| Amryt Pharma Holdings LTD | $15.53 | 2023 | Mycapssa |
| Recordati_rare_diseases_inc. | $13.06 | 2023 | Signifor Lar, Isturisa |
| Takeda Pharmaceuticals U.S.A., INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aashish Samat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.